In conclusion, correction of anemia (Hb levels 12.5–13.5 mg/dL) with an ESA showing a longer half-life prevents the progression of chronic allograft nephropathy in KTx recipients, as long as BP is appropriately controlled. This evidence concerns the gene GSTM1 and Crouzon syndrome-acanthosis nigricans syndrome.